- Suppliers
Biogrund 
Evonik 
Capsugel Lonza 
Roquette 
ADM 
Antares 
Armor Pharma 
Asahi KASEI 
Ashland 
BASF 
Beneo 
Captisol 
CarboHyde 
Clariant 
Croda 
DFE Pharma 
Dow 
Excipio Chemicals 
Fuji Chemical 
Gangwal 
Gattefossé 
Grace 
Indovinya 
Ingredient Pharm 
IOI Oleo 
JRS Pharma 
KLK Oleo 
Lactalis 
Lipoid 
Lubrizol Life Science Health 
MAGNESIA 
MEGGLE 
Mingtai Chemical 
Nagase Viita 
Nomisma 
Nordic Bioproducts 
PMC Isochem 
PQ 
Seppic 
ShinEtsu 
Sigachi 
SPI Pharma 
Vikram Thermo 
All4Nutra
- Suppliers
Biogrund Evonik Capsugel Lonza Roquette ADM Antares Armor Pharma Asahi KASEI Ashland BASF Beneo Captisol CarboHyde Clariant Croda DFE Pharma Dow Excipio Chemicals Fuji Chemical Gangwal Gattefossé Grace Indovinya Ingredient Pharm IOI Oleo JRS Pharma KLK Oleo Lactalis Lipoid Lubrizol Life Science Health MAGNESIA MEGGLE Mingtai Chemical Nagase Viita Nomisma Nordic Bioproducts PMC Isochem PQ Seppic ShinEtsu Sigachi SPI Pharma Vikram Thermo - All4Nutra
A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose
SEM image of FMXIN001 new dry powder-based formulation
Objective
To examine the pharmacokinetics and safety of FMXIN001, a new intranasal powder-based naloxone formulation, in comparison to Narcan® nasal liquid spray.
Methods
FMXIN001, was developed by blending drug microspheres with larger lactose monohydrate particles, that serve as diluent and carrier, as well as a disaggregating agent. Scanning electron microscopy and X-ray were used to characterize the formulation and in vitro deposition was investigated using a nasal cast.
We compared the pharmacokinetics and safety of FMXIN001 versus Narcan® in two clinical trials: a pilot study with 14 healthy adults and a pivotal trial in 42 healthy adults (NCT04713709). The studies were open-label, single-dose, randomized, two-period, two-treatment, two-sequence crossover studies to assess the pharmacokinetics and safety of FMXIN001 versus Narcan® nasal spray.
Results
FMXIN001 comprises naloxone microspheres (5-30 μM) and lactose particles (40–240 μM). Upon in vitro testing, naloxone deposits mainly to the middle turbinates region and the upper part of the nasal cavity of a nasal cast. In human subjects, FMXIN001 produced significantly higher exposure at the initial time points of 4, 10, and 30 min, post-administration, compared to Narcan®. Both treatments were safe and well tolerated. FMXIN001, powder-based spray, results in similar overall exposure to Narcan®, but with more rapid absorption in the first 30 min.
Conclusions
FMXIN001 is expected to have a shorter onset of action for a more effective therapeutic intervention to manage opioid overdose. Rapid administration of naloxone in cases of opioid overdose is imperative, given the alarming increase in mortality rates.
Continue reading here
About this article: Lapidot, T., Bouhajib, M., Faulknor, J. et al. A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose. Pharm Res (2022). https://doi.org/10.1007/s11095-022-03247-5
